

**FMHL/SE/BM/FEB'26**

**February 06, 2026**

BSE Limited  
Department of Corporate Services  
Phiroze Jegjeebhoy Towers,  
Dalal Street, Mumbai - 400001

**Scrip Code: 523696**

**Subject: Outcome of Board Meeting in accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015 (“SEBI Listing Regulations”) this is to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday, February 6, 2026, inter-alia, considered and approved the following matter: -

**1. Financial Results**

Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and period ended December 31, 2025 (“**Quarterly Results**”).

Accordingly, please find enclosed herewith Un-Audited Standalone and Consolidated Financial Results of the Company along with limited review report given by the Statutory Auditor of the Company for the quarter and period ended December 31, 2025.

**2. Appointment of Director**

Subject to Shareholders approval, appointment of Mr. Bidesh Chandra Paul. (DIN: 08596135) as a Director of the Company, effective from January 18, 2026, closing of business hours and to designate him as a Whole- time Director & KMP of the Company (Tenure for WTD and KMP- 3 years), effective from February 6, 2026.

**3. Re-appointment of Directors**

Subject to Shareholders approval, re-appointment of Ms. Shailaja Chandra (DIN: 03320688) as an Independent Director of the Company for a second term of period of five (5) consecutive years commencing from March 10, 2026.

The detailed disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 for above mentioned items (2) and (3) is enclosed herewith as **Annexure-I**.

---

**FORTIS MALAR HOSPITALS LIMITED**

**Regd. Office:** Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 **Tel:** +0172-4692222 **Fax:** +91 172 5096002  
**CIN:** L85110PB1989PLC045948 **Email:** [secretarial.malar@malarhospitals.in](mailto:secretarial.malar@malarhospitals.in)  
**Website:** [www.fortismalarhospital.com](http://www.fortismalarhospital.com)



The Board Meeting commenced at 11.30 AM IST and concluded at 3:30 PM IST.

This is for your information and record please.

Thanking You,  
**For Fortis Malar Hospitals Limited**

**Vinti Verma**  
**Company Secretary & Compliance Officer**  
**ICSI Membership No. A44528**

Encl.: as above

---

**FORTIS MALAR HOSPITALS LIMITED**

**Regd. Office:** Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 **Tel:** +0172-4692222 **Fax:** +91 172 5096002  
**CIN:** L85110PB1989PLC045948 **Email:** [secretarial.malar@malarhospitals.in](mailto:secretarial.malar@malarhospitals.in)  
**Website:** [www.fortismalarhospital.com](http://www.fortismalarhospital.com)

### Annexure I

Disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

S. No.	Particulars	Description	
1.	Name of the Director	Mr. Bidesh Chandra Paul	Ms. Shailaja Chandra
2.	Reason for change viz. appointment, resignation, removal, death or otherwise.	Subject to Shareholders approval, appointment of Mr. Bidesh Chandra Paul. (DIN: 08596135) as a Director of the Company, effective from January 18, 2026, closing of business hours and of five (5) consecutive years to designate him as a Whole- time Director & KMP of the Company (Tenure for WTD and KMP- 3 years), effective from February 6, 2026	Re-appointment of Ms. Shailaja Chandra (DIN: 03320688) as an Independent Director of the Company for a second term of period of five (5) consecutive years commencing from March 10, 2026
3.	Date of appointment/ cessation (as applicable) & term of appointment	Subject to Shareholders approval, the appointment as a director of the Company effective from January 18, 2026 and as a Whole- time Director & KMP of the Company (Tenure for WTD and KMP- 3 years), effective from February 6, 2026.	Subject to Shareholders approval, the with effective from March 10, 2026.
4.	Brief profile (in case of appointment).	<p>Mr. Bidesh Chandra Paul is a healthcare and operations leader with over 15 years of experience in manufacturing, R&amp;D, healthcare operations and supply chain management.</p> <p>He holds a Dual Degree (B.Tech &amp; M.Tech) from IIT Kharagpur and a Post Graduate Programme (PGP) from IIM Bangalore.</p> <p>Since joining Fortis in August 2019, he has driven significant strategic and operational outcomes.</p> <p>In his recent role as Vice President and Zonal Director, he was responsible for</p>	<p>Ms. Shailaja Chandra has spent over 20 years in the health sector and was a Secretary in the Ministry of Health &amp; Family Welfare, Government of India and later Delhi's only woman Chief Secretary.</p> <p>She has been a career civil servant (a member of the Indian Administrative Service) for 38 years followed by a series of post-retirement assignments carrying executive responsibilities. During her long service career in the Central Government, she was posted over three tenures with the Ministries of Defence, Power and Health. At the</p>

#### **FORTIS MALAR HOSPITALS LIMITED**

**Regd. Office:** Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 **Tel:** +0172-4692222 **Fax:** +91 172 5096002

**CIN:** L85110PB1989PLC045948 **Email:** [secretarial.malar@malarhospitals.in](mailto:secretarial.malar@malarhospitals.in)

**Website:** [www.fortismalarhospital.com](http://www.fortismalarhospital.com)

	<p>the P&amp;L of Fortis Heart Institute, Okhla (310 beds) and Fortis CDOC (25 beds), delivering 31% revenue growth over four years and turning the unit's EBITDA positive. He also diversified service offerings beyond cardiac care and successfully transformed the previously loss-making CDOC into an EBITDA-neutral hospital.</p> <p>Prior to Fortis, Mr. Paul held senior operations and leadership roles at Narayana Healthcare and TVS Motors, where he led multi-specialty hospital turnarounds, improved financial and operational performance, and introduced critical supply chain and inventory efficiency measures.</p>	<p>state level, Ms. Chandra was posted across the country in Maharashtra, Manipur, Goa, Delhi and the Andaman &amp; Nicobar Islands.</p> <p>Since retirement Ms. Chandra has held Board/ Management Committee level positions under the Government, the NGO sector as well as listed Indian companies.</p> <p>She is a prolific writer and is regularly invited as a policy analyst by the print and electronic media to comment on matters of Governance, Health, Gender and current developments in Delhi, the capital of India. She has been invited several times to Chair or speak at International conferences, organised by OECD as well as by Indian Universities, think tanks and health related forums.</p>
5.	Disclosure of relationships between directors (in case of appointment of a director).	Mr. Bidesh Chandra Paul is not related to any of the other Directors of the Company
6.	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/24 dated June 20, 2018 issued by the BSE.	Mr. Bidesh Chandra Paul is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority

---

**FORTIS MALAR HOSPITALS LIMITED**

**Regd. Office:** Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062 **Tel:** +0172-4692222 **Fax:** +91 172 5096002  
**CIN:** L85110PB1989PLC045948 **Email:** [secretarial.malar@malarhospitals.in](mailto:secretarial.malar@malarhospitals.in)  
**Website:** [www.fortismalarhospital.com](http://www.fortismalarhospital.com)

**Limited Review Report on unaudited consolidated financial results of Fortis Malar Hospitals Limited for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To the Board of Directors of Fortis Malar Hospitals Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Fortis Malar Hospitals Limited (hereinafter referred to as "the Parent"), and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:
  - a. Fortis Malar Hospitals Limited
  - b. Fortis Healthcare Research Foundation (Formerly known as "Malar Stars Medicare Limited")
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Registered Office:

**Limited Review Report (Continued)**

**Fortis Malar Hospitals Limited**

6. We draw attention to Note 5 to the Statement which explains that consequent to sale of business operations through a slump sale transaction, the Parent ceases to have any business operations. While there is no visibility of commencing any new business operations in the future, the Parent's management and Board of Directors is currently evaluating various corporate restructuring options for the future possible course of actions for the Parent and is progressing with the finalisation of plan. However, the Parent believes that it has sufficient cash and cash equivalent and other bank balances to settle its obligations as and when they fall due, and it believes that it would be able to meet its financial requirements for the foreseeable future based on the current cash position and projected cash flows. Accordingly, these unaudited consolidated financial results have been prepared on a going concern basis.

Our conclusion is not modified in respect of this matter.

**For B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022



Varun Kumar Tyagi

*Partner*

Gurugram

Membership No.: 518152

06 February 2026

UDIN: 26518152VHKHCQ8558

**Limited Review Report on unaudited standalone financial results of Fortis Malar Hospitals Limited for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To the Board of Directors of Fortis Malar Hospitals Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Fortis Malar Hospitals Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 *"Interim Financial Reporting"* ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to Note 5 to the Statement which explains that consequent to sale of business operations through a slump sale transaction, the Company ceases to have any business operations. While there is no visibility of commencing any new business operations in the future, the Company's management and Board of Directors is currently evaluating various corporate restructuring options for the future possible course of actions for the Company and is progressing with the finalisation of plan. However, the Company believes that it has sufficient cash and cash equivalent and other bank balances to settle its obligations as and when they fall due, and it believes that it would be able to meet its financial requirements for the foreseeable future based on the current cash position and projected cash flows. Accordingly, these unaudited standalone financial results have been prepared on a going concern basis.

Our conclusion is not modified in respect of this matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.101248W/W-100022

Varun Kumar Tyagi  
Partner

Membership No.: 518152

UDIN: 26518152HLRWCQ4888

Registered Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Gurugram  
06 February 2026

No.	Particulars	(Rs. In lakhs except equity share data)												
		Standalone			Standalone			Standalone Year ended	Consolidated			Consolidated		Consolidated Year ended
		Quarter ended	September 30, 2025	December 31, 2024	Nine months ended	December 31, 2025	December 31, 2024		March 31, 2025	December 31, 2025	September 30, 2025	December 31, 2024	December 31, 2025	December 31, 2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income</b>													
	a) Grant income	-	-	-	-	-	-	-	0.25	2.50	-	4.80	-	-
	b) Other income (refer note 8)	52.11	51.72	56.04	564.55	194.99	271.72	52.11	51.72	56.04	564.55	194.99	194.99	271.72
	<b>Total income</b>	<b>52.11</b>	<b>51.72</b>	<b>56.04</b>	<b>564.55</b>	<b>194.99</b>	<b>271.72</b>		<b>52.36</b>	<b>54.22</b>	<b>56.04</b>	<b>569.35</b>	<b>194.99</b>	<b>271.72</b>
<b>2</b>	<b>Expenses</b>													
	a) Purchase of medical consumables and drugs	-	-	-	-	-	-	-	-	-	-	-	-	-
	b) Changes in inventories of medical consumables and drugs	-	-	-	-	-	-	-	-	-	-	-	-	-
	c) Employee benefits expense	2.20	2.20	1.07	6.60	48.55	40.76	2.20	2.20	1.07	6.60	48.55	40.76	40.76
	d) Finance costs	-	-	0.36	-	1.02	1.02	-	-	-	-	1.02	1.02	1.02
	e) Depreciation and amortization expenses	-	-	-	-	-	-	-	-	-	-	-	-	-
	f) Project expenses	-	-	-	-	-	-	-	-	-	-	-	-	-
	g) Other expenses	28.90	34.51	39.31	91.05	126.59	171.35	30.95	35.11	39.84	98.13	128.27	173.13	173.13
	<b>Total expenses</b>	<b>31.10</b>	<b>36.71</b>	<b>40.74</b>	<b>97.65</b>	<b>176.16</b>	<b>213.13</b>	<b>33.40</b>	<b>39.78</b>	<b>41.27</b>	<b>107.45</b>	<b>177.84</b>	<b>214.91</b>	<b>214.91</b>
<b>3</b>	<b>Profit / (loss) before exceptional items and taxes (1-2)</b>	<b>21.01</b>	<b>15.01</b>	<b>15.30</b>	<b>466.90</b>	<b>18.83</b>	<b>58.59</b>	<b>18.96</b>	<b>14.44</b>	<b>14.77</b>	<b>461.90</b>	<b>17.15</b>	<b>56.81</b>	<b>56.81</b>
<b>4</b>	<b>Exceptional items</b>	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>5</b>	<b>Profit / (loss) after exceptional items and before tax(3+4)</b>	<b>21.01</b>	<b>15.01</b>	<b>15.30</b>	<b>466.90</b>	<b>18.83</b>	<b>58.59</b>	<b>18.96</b>	<b>14.44</b>	<b>14.77</b>	<b>461.90</b>	<b>17.15</b>	<b>56.81</b>	<b>56.81</b>
<b>6</b>	<b>Tax expense</b>	<b>17.42</b>	<b>13.02</b>	<b>14.00</b>	<b>42.66</b>	<b>14.00</b>	<b>17.59</b>	<b>17.42</b>	<b>13.02</b>	<b>14.00</b>	<b>43.66</b>	<b>14.00</b>	<b>17.61</b>	<b>17.61</b>
	- Current tax	13.11	13.02	-	39.35	-	3.59	13.11	13.02	-	39.35	-	3.59	3.59
	- Earlier year income tax	4.31	-	14.00	4.31	14.00	14.00	4.31	-	14.00	4.31	14.00	14.00	14.02
	- Deferred tax charged/ (credit)	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>7</b>	<b>Profit / (loss) after tax (5-6)</b>	<b>3.59</b>	<b>1.99</b>	<b>1.30</b>	<b>423.24</b>	<b>4.83</b>	<b>41.00</b>	<b>1.54</b>	<b>1.42</b>	<b>0.77</b>	<b>418.24</b>	<b>3.15</b>	<b>39.20</b>	<b>39.20</b>
	Other comprehensive income / (loss) (net of tax)	-	-	-	-	-	-	-	-	-	-	-	-	-
	Items that will not be reclassified subsequently to the statement of profit and loss:	-	-	-	-	-	-	-	-	-	-	-	-	-
	(a) Remeasurements of defined benefit liability	-	-	-	-	-	-	-	-	-	-	-	-	-
	(b) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>8</b>	<b>Other comprehensive income / (loss) (net of tax)</b>	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>9</b>	<b>Total comprehensive income / (loss) for the period / year (7+8)</b>	<b>3.59</b>	<b>1.99</b>	<b>1.30</b>	<b>423.24</b>	<b>4.83</b>	<b>41.00</b>	<b>1.54</b>	<b>1.42</b>	<b>0.77</b>	<b>418.24</b>	<b>3.15</b>	<b>39.20</b>	<b>39.20</b>
	Total comprehensive income / (loss) attributable to:	-	-	-	-	-	-	-	-	-	-	-	-	-
	- Owners of the company	3.59	1.99	1.30	423.24	4.83	41.00	1.54	1.42	0.77	418.24	3.15	39.20	39.20
	- Non-controlling interests	NA	NA	NA	NA	NA	NA	-	-	-	-	-	-	-
<b>10</b>	<b>Paid up equity share capital (face value Rs.10 each)</b>	<b>1,875.70</b>	<b>1,875.70</b>	<b>1,875.70</b>	<b>1,875.70</b>	<b>1,875.70</b>	<b>1,875.70</b>	<b>1,875.70</b>	<b>1,875.70</b>	<b>1,875.70</b>	<b>1,875.70</b>	<b>1,875.70</b>	<b>1,875.70</b>	<b>1,875.70</b>
<b>11</b>	<b>Reserves excluding revaluation reserves - other equity</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>1,120.71</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>	<b>1,145.21</b>
<b>12</b>	<b>Earnings Per Share (EPS) based on (7) above (of Rs. 10 each) - (Not annualized in the quarters)</b>	- Basic	0.02	0.01	0.01	2.26	0.03	0.22	0.01	0.01	0.00	2.23	0.02	0.21
	- Diluted	0.02	0.01	0.01	2.26	0.03	0.22	0.01	0.01	0.00	2.23	0.02	0.21	

*Rakesh*  
 FORTIS MALAR HOSPITALS LTD.

**FORTIS MALAR HOSPITALS LIMITED (CIN: L85110PB1989PLC045948)**

Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali-160062

Tel Numbers: 0172 5096001 & Tele Fax No : 0172 5096002

Website: [www.fortismalarhospital.com](http://www.fortismalarhospital.com); Email: [secretarial.malar@malarhospitals.in](mailto:secretarial.malar@malarhospitals.in)

**STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025**

**Notes:**

- 1 The unaudited standalone and consolidated financial results of Fortis Malar Hospitals Limited ("the Company") for the quarter and nine months ended December 31, 2025 has been reviewed by the Audit and Risk Management Committee and subsequently approved by the Board of Directors at their respective meeting held on February 6, 2026. The above results have been subjected to limited review by the Statutory auditors of the Company. The auditors have issued an unmodified review report.
- 2 These unaudited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The consolidated financial results include the financial results of the Company Fortis Malar Hospitals Limited and the financial results of its subsidiary company Fortis Healthcare Research Foundation (Formerly known as Malar Stars Medicare Limited), (collectively known as "Group").
- 4 The Company is engaged in the Healthcare Services, which in the context of Indian Accounting Standard (Ind AS) 108 - Operating Segments is considered as the only reportable segment of the Company. Also refer note 5 below.
- 5 During the year ended March 31, 2024, the Company had entered into Business Transfer Agreement ("BTA") with MGM Healthcare Private Limited ("MGM") for the sale of its business operations pertaining to Malar Hospital, as a going concern, on a slump sale basis. Post the slump sale transaction, the Company ceases to have any business operations. Currently, the management of the Company has no visibility of commencing any new business operations in the future and the Company's management and Board of Directors, in consultation with its legal advisors/ merchant bankers, is evaluating various corporate restructuring options for the future possible course of actions for the Company and is progressing with the finalisation of plan. The Company's cash and cash equivalent and other bank balances (~Rs 3,251.64 lakhs) would be sufficient to settle its obligations as and when they fall due. Based on the current cash position and projected cash flows, the Company believes that it would be able to meet its financial obligations for the foreseeable future such as ongoing expenses for running the Company, resolving medico legal cases (claim amount:-Rs 649.40 lakhs), VAT appeals (tax demand: ~Rs 254.93 lakhs), GST appeal (tax demand: ~Rs 22.23 lakhs) and Income tax appeal (tax demand ~Rs 171.43 lakhs) which are being contested. As a matter of abundant caution these details are being disclosed herein and should not be construed in any manner as admission of any liability or breach. Any financial exposure in respect of medico legal cases, VAT appeals, GST appeal and Income tax appeal are currently estimated and assessed by management as remote. Accordingly, these standalone and consolidated financial results have been prepared on a going concern basis.
- 6 During the previous year, the Company had received show cause notices totalling to Rs 22,535.42 lakhs from GST authority for the period from July, 2017 to March, 2024, wherein they had proposed to levy GST on various items including depreciation, employee salaries, exempt healthcare services, interest expenses, trade payables, etc., on which either GST is not leviable or on which GST had already been paid, and also GST authority had proposed to disallow GST input tax credit, which had never been claimed by the Company. Subsequent to the issuance of the show cause notices, the Company has received adjudication orders for all the relevant periods. Against the proposed aggregate demand of Rs. 22,535.42 lakhs for the said periods as per above referred show cause notices, the adjudicated demand has been reduced to Rs. 22.23 lakhs for the period from July, 2017 to March, 2023 with Nil demand for the financial year 2023-24. The Company has filed appeals against the adjudication order pertaining to the period July 2017 to March 2019 and is in process of filling the appeals for the FY 2019-20 to FY 2022-23.
- 7 During the quarter ended June 30, 2025, Malar Stars Medicare Limited, the subsidiary company, filed an application with the Ministry of Corporate Affairs, for conversion into a Section 8 Company, as per the provisions of the Companies Act, 2013. The application has been approved by Ministry of Corporate Affairs and is effective from May 14, 2025. Consequently, the name of the subsidiary Company has also been changed from 'Malar Stars Medicare Limited' to 'Malar Star Medicare'. Further, the name of the subsidiary Company has been changed from 'Malar Star Medicare' to 'Fortis Healthcare Research Foundation' with effect from August 26, 2025.
- 8 Pursuant to the notification dated June 11, 2025 issued by the Government of Tamil Nadu, regarding the revision of minimum wage rates, the Company has reversed the provision of Rs 408.20 lakhs towards earlier minimum wages payable. The provision written back has been considered as other income in the standalone and consolidated financial results for the quarter ended June 30, 2025.
- 9 In light of the acquisition of the controlling stake of FHL by Northern TK Venture Pte Limited ("NTK") ("Acquirer") a wholly owned subsidiary of IHH Healthcare Berhad, Malaysia, a mandatory open offer got triggered for acquisition by NTK of up to 4,894,308 fully paid up equity shares of face value of INR 10 each in the Company, representing 26% of the paid-up equity shares of the Company at a price of Rs. 60.10 per share ("Malar Open Offer") in December 2018. However, in view of order dated December 14, 2018 passed by Hon'ble Supreme Court wherein it was specified that status quo with regard to sale of the controlling stake in Fortis Healthcare Limited to IHH Healthcare Berhad, Malaysia be maintained ("Status Quo Order"), the Mandatory Open offer was kept in abeyance. The Hon'ble Supreme Court vide its final judgment dated September 22, 2022 ("2022 Judgment") disposed of the petitions with certain directions to the Hon'ble High Court of Delhi. Basis legal advice, it is understood that pursuant to the 2022 Judgment, the Status Quo Order, being an interim order, ceases to exist and stands merged with the 2022 Judgment.
- On October 16, 2025, the Company made a Disclosure in respect of the announcement made by IHH Healthcare Berhad ("IHH") dated October 16, 2025 on the Malaysian Stock Exchange (i.e. Bursa Malaysia) regarding the Malar Open Offer [open offer price was revised from the original open offer price of INR 60.10 (Indian Rupees Sixty and Ten Paisa only) per Equity Share to INR 17.60 (Indian Rupees Seventeen and Sixty Paisa only), in accordance with the requirements of the SEBI (SAST) Regulations]. Basis announcement made by IHH dated November 11 2025, following the completion of the transfer of Malar Shares from the tendering shareholders to the Acquirer and the completion and settlement of payment to the tendering shareholders of the Company, the Malar Open Offer has been completed on November 10, 2025.
- 10 These financial results are available on the BSE website ([www.bseindia.com](http://www.bseindia.com)) and on the Company's website ([www.fortismalarhospital.com](http://www.fortismalarhospital.com)).

By Order of the Board  
Fortis Malar Hospitals Limited  
CIN: L85110PB1989PLC045948

Bidesh Chandra Paul  
Whole Time Director  
DIN: 08596135  
Place : Gurugram  
Date: February 6, 2026

